Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Cash from Operations: 2017-2025

Historic Cash from Operations for Dianthus Therapeutics (DNTH) over the last 6 years, with Sep 2025 value amounting to -$30.6 million.

  • Dianthus Therapeutics' Cash from Operations fell 43.67% to -$30.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$109.5 million, marking a year-over-year decrease of 74.98%. This contributed to the annual value of -$78.2 million for FY2024, which is 112.09% down from last year.
  • According to the latest figures from Q3 2025, Dianthus Therapeutics' Cash from Operations is -$30.6 million, which was down 27.89% from -$23.9 million recorded in Q2 2025.
  • In the past 5 years, Dianthus Therapeutics' Cash from Operations ranged from a high of $16.4 million in Q3 2022 and a low of -$30.6 million during Q3 2025.
  • In the last 3 years, Dianthus Therapeutics' Cash from Operations had a median value of -$14.9 million in 2024 and averaged -$17.9 million.
  • In the last 5 years, Dianthus Therapeutics' Cash from Operations skyrocketed by 71.93% in 2023 and then slumped by 207.08% in 2024.
  • Dianthus Therapeutics' Cash from Operations (Quarterly) stood at -$8.9 million in 2022, then tumbled by 33.93% to -$11.9 million in 2023, then slumped by 131.52% to -$27.4 million in 2024, then plummeted by 43.67% to -$30.6 million in 2025.
  • Its Cash from Operations stands at -$30.6 million for Q3 2025, versus -$23.9 million for Q2 2025 and -$27.6 million for Q1 2025.